ProCE Banner Activity

Preview of Hot Topics at ASH 2018: Key Expert-Selected Studies

Conference Coverage
Clinical Thought
Experts highlight key data to help you learn what to expect at the upcoming Hematology meeting in San Diego. The CCO ASH Conference Coverage program will feature downloadable slides and expert analysis of these and dozens of other clinically relevant studies presented at ASH. We will have the information you need to understand and integrate the latest hematology data into your practice.

Released: November 27, 2018

Expiration: November 26, 2019

Share

Faculty

John M. Burke

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

Jeffrey P. DONOTUSESharman

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Sagar Lonial

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Keith W. Pratz

Keith W. Pratz, MD

Assistant Professor of Oncology
Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Farhad Ravandi

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology

Faculty Disclosure

Primary Author

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

John M. Burke, MD, has disclosed that he has served on advisory boards for AbbVie, Celgene/Juno, Genentech/AbbVie, Gilead Sciences /Kite, Seattle Genetics, and Tempus Labs and on the speaker bureau for Seattle Genetics.

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff P. Sharman, MD, has disclosed that he has received consulting fees and funds for research support from AbbVie, Celgene, Genentech, Gilead Sciences, Pharmacyclics, and TG Therapeutics.

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, Celgene, Dr. Reddy’s Laboratory, Genentech, Janssen, Kite, MedImmune, Merck, Oncopeptides, and Takeda and funds for research support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Kite, MedImmune, Merck, Novartis, Roche/Genentech, Sanofi, and Takeda.

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Janssen, Karyopharm, Merck, Novartis, and Takeda.

Keith W. Pratz, MD

Assistant Professor of Oncology
Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Keith W. Pratz, MD, has disclosed that he has received consulting fees from AbbVie, Astellas, and Boston Biomedical and funds for research support AbbVie, Agios, Astellas, and Millenium/Takeda

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Farhad Ravandi, MD, has disclosed that he has received consulting fees from Agios, Amgen, Ariad, Astellas, Jazz, and Orsenix and funds for research support AbbVie, Amgen, Bristol-Myers Squibb, Seattle Genetics, and Xencor.